Nephroprotective Effects of 2nd Type Sodium-Glucose Co-Transporter Inhibitors: A Literature Review

Authors

  • Botir Daminov1, Sherzod Abdullaev2, Rano Igamberdieva3, Olimkhon Sharapov4

DOI:

https://doi.org/10.37506/ijfmt.v14i4.12865

Keywords:

Diabetes mellitus, oral hypoglycemic drugs, 2nd type sodium-glucose cotransporter inhibitors, chronic kidney disease, diabetic nephropathy, nephroprotection

Abstract

Introduction: A wide range of oral hypoglycemic drugs with various mechanisms of effect are available for
the treatment of patients with 2nd type diabetes mellitus today. Despite the high effectiveness of these agents
in the normalization of glycemia, they cause different chronic complications in many patients with 2nd type
diabetes mellitus. However, during the last years, a range of principal new data has been accumulated on
the pleiotropic effects of the last classes of oral hypoglycemic agents — inhibitors of the 2nd type sodiumglucose
cotransporter (SGLT2).
Materials and Method: Three electronic databases were checked to find out studies reporting the data on
the mechanisms and clinical significance of the nephroprotective effect of inhibitors of the sodium-glucose
cotransporter of 2nd type (glyphlozines) in patients with 2nd type diabetes mellitus. The primary outcome
was to learn the worldwide tendency on this matter and to compare the results of different researchers.
Results: We found 25 studies as eligible for our review. The review presents data on the mechanisms and
clinical significance of the nephroprotective effect of inhibitors of the sodium-glucose cotransporter of 2nd
type (glyphlozines). The effects associated with the influence of representatives of this pharmacological
group on the glomerular filtration rate, glycemia, diuresis, ketogenesis and other factors are discussed. The
results of recent experimental and clinical studies aimed at studying certain aspects of the nephroprotective
effect of SGLT2 inhibitors in 2nd type diabetes mellitus and other pathological conditions were analyzed.
Conclusion. SGLT2 inhibitors associate with a multicomponent nephroprotective effect, which confirmed
by the results of both experimental and clinical studies. The nephroprotective potential of SGLT2 inhibitors
is maximally realized in the presence of diabetes and remains not entirely clear in the case of another kidney
pathology.

Author Biography

  • Botir Daminov1, Sherzod Abdullaev2, Rano Igamberdieva3, Olimkhon Sharapov4

    1MD, Professor, Rector of Tashkent Pediatric Medical Institute, 223 Bogishamol Str., Yunusobod district, Tashkent,
    Uzbekistan, 2Doctor of medical sciences, MD, teaching assistant, Department of Faculty Internal Diseases,
    military field therapy, occupational pathology, hospital internal diseases and Propaedeutic of internal diseases,
    Tashkent Pediatric Medical Institute, 223 Bogishamol Str., Yunusobod district, Tashkent, Uzbekistan, 3MD,
    Teaching assistant, PhD, Department of Faculty Internal Diseases, military field therapy, occupational pathology,
    hospital internal diseases and Propaedeutic of internal diseases, Tashkent Pediatric Medical Institute, 223
    Bogishamol Str., Yunusobod district, Tashkent, Uzbekistan, 4MD, Teaching assistant, PhD, Department of Faculty
    Internal Diseases, military field therapy, occupational pathology, hospital internal diseases and Propaedeutic
    of internal diseases, Tashkent Pediatric Medical Institute, 223 Bogishamol Str., Yunusobod district, Tashkent,
    Uzbekistan

Downloads

Published

2020-10-29

Issue

Vol. 14 No. 4 (2020): Indian Journal of Forensic Medicine & Toxicology

Section

Articles

License

https://creativecommons.org/licenses/by-nc/2.0/deed.en

How to Cite

Nephroprotective Effects of 2nd Type Sodium-Glucose Co-Transporter Inhibitors: A Literature Review. (2020). Indian Journal of Forensic Medicine & Toxicology, 14(4), 7706-7716. https://doi.org/10.37506/ijfmt.v14i4.12865